학술논문
Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trial
Document Type
Article
Author
Mallory, R.M.; Formica, N.; Pfeiffer, S.; Wilkinson, B.; Marcheschi, A.; Albert, G.; McFall, H.; Robinson, M.; Plested, J.S.; Zhu, M.; Cloney-Clark, S.; Zhou, B.; Chau, G.; Robertson, A.; Maciejewski, S.; Smith, G.; Patel, N.; Glenn, G.M.; Hammond, H.L.; Baracco, L.; Logue, J.; Frieman, M.B.; Adams, M.; Arya, M.; Athan, E.; Berger, I.; Bradley, P.; Briskin, T.; Glover II, R.; Griffin, P.; Kim, J.; Kitchener, S.; Klein, T.; Leah, A.; Leelasena, I.; Lemech, C.; Lickliter, J.; Manning, M.B.; Napier-Flood, F.; Nugent, P.; Thackwray, S.; Turner, M.
Source
In: The Lancet Infectious Diseases . (The Lancet Infectious Diseases, November 2022, 22(11):1565-1576)
Subject
Language
English
ISSN
14744457
14733099
14733099